Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth

Johnson & Johnson’s MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release.

The segment slightly outpaced the healthcare solution provider’s other segment, Innovative Medicine, whose worldwide operational sales were up 5.3% year over year, reaching about $60.4 billion, according to the release.

“Our success over the last year was supported by 15 major launches and more than 40 regulatory approvals in major markets, and with more than 60 active clinical trials, we have significant momentum going into 2026,” Joaquin Duato, chairman and CEO of Johnson & Johnson, said Wednesday during the company’s fourth quarter and full year earnings call.

The MedTech segment’s growth was led by electrophysiology products and Abiomed in the Cardiovascular area and wound closure products in General Surgery, together with the acquisition of Shockwave, the release said. Duato said during the call that Abiomed delivered operational growth of 18% in the fourth quarter, while Shockwave delivered 23%.

Johnson & Johnson completed its acquisition of Shockwave, an intravascular lithotripsy platform for coronary artery disease, in May 2024. The company said at the time that this move would bring Shockwave technology to more patients and boost the technology’s annual sales to at least $1 billion.

During 2025, the company’s Shockwave and Carvykti platforms each surpassed $1 billion in annual sales for the first time, bringing to 28 the number of platforms that generate at least that much annual revenue, according to a presentation released Wednesday.

Looking ahead, Johnson & Johnson expects its overall worldwide operational sales to see year-over-year growth of between 5.7% and 6.2%, which could take the company over the $100 billion milestone. The firm expects its operational sales to total between $99.5 billion and $100.5 billion, according to the release.

Duato said during the earnings call that Johnson & Johnson will soon become the only healthcare company delivering over $100 billion in revenue.

“How is that possible? It’s possible because we have tremendous strength and depth, both in Innovative Medicine and in MedTech,” Duato said. “We are different from other companies. We are not focused on one or two growth drivers.”